BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010;29:44. [PMID: 20459683 DOI: 10.1186/1756-9966-29-44] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Sun Y, Tan L, Neuman RI, Broekhuizen M, Schoenmakers S, Lu X, Danser AHJ. Megalin, Proton Pump Inhibitors and the Renin-Angiotensin System in Healthy and Pre-Eclamptic Placentas. Int J Mol Sci 2021;22:7407. [PMID: 34299027 DOI: 10.3390/ijms22147407] [Reference Citation Analysis]
2 Notte A, Ninane N, Arnould T, Michiels C. Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation. Cell Death Dis. 2013;4:e638. [PMID: 23681233 DOI: 10.1038/cddis.2013.167] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.9] [Reference Citation Analysis]
3 Oot RA, Couoh-Cardel S, Sharma S, Stam NJ, Wilkens S. Breaking up and making up: The secret life of the vacuolar H+ -ATPase. Protein Sci 2017;26:896-909. [PMID: 28247968 DOI: 10.1002/pro.3147] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
4 Wang BY, Zhang J, Wang JL, Sun S, Wang ZH, Wang LP, Zhang QL, Lv FF, Cao EY, Shao ZM, Fais S, Hu XC. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 2015;34:85. [PMID: 26297142 DOI: 10.1186/s13046-015-0194-x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 12.0] [Reference Citation Analysis]
5 Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011;226:299-308. [PMID: 20857482 DOI: 10.1002/jcp.22400] [Cited by in Crossref: 220] [Cited by in F6Publishing: 210] [Article Influence: 20.0] [Reference Citation Analysis]
6 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
7 Walsh M, Fais S, Spugnini EP, Harguindey S, Abu Izneid T, Scacco L, Williams P, Allegrucci C, Rauch C, Omran Z. Proton pump inhibitors for the treatment of cancer in companion animals. J Exp Clin Cancer Res 2015;34:93. [PMID: 26337905 DOI: 10.1186/s13046-015-0204-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
8 Kallifatidis G, Hoepfner D, Jaeg T, Guzmán EA, Wright AE. The marine natural product manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Mar Drugs 2013;11:3500-16. [PMID: 24048269 DOI: 10.3390/md11093500] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
9 Ganguly A, Chakraborty P, Banerjee K, Choudhuri SK. The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. Eur J Pharm Sci 2014;51:96-109. [PMID: 24044945 DOI: 10.1016/j.ejps.2013.09.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
10 Yin Z, Yu M, Ma T, Zhang C, Huang S, Karimzadeh MR, Momtazi-Borojeni AA, Chen S. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J Immunother Cancer 2021;9:e001698. [PMID: 33472857 DOI: 10.1136/jitc-2020-001698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
11 Chang FY, Kawashima SA, Brady SF. Mutations in the proteolipid subunits of the vacuolar H+-ATPase provide resistance to indolotryptoline natural products. Biochemistry 2014;53:7123-31. [PMID: 25319670 DOI: 10.1021/bi501078j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
12 Lu ZN, Tian B, Guo XL. Repositioning of proton pump inhibitors in cancer therapy. Cancer Chemother Pharmacol 2017;80:925-37. [PMID: 28861639 DOI: 10.1007/s00280-017-3426-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
13 Kulkarni H, Göring HH, Curran JE, Diego V, Dyer TD, Cole S, Walder KR, Collier GR, Blangero J, Carless MA. Genetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells. Cancer Chemother Pharmacol 2013;71:1095-100. [PMID: 23420437 DOI: 10.1007/s00280-013-2110-4] [Reference Citation Analysis]
14 Fais S, Marunaka Y. The Acidic Microenvironment: Is It a Phenotype of All Cancers? A Focus on Multiple Myeloma and Some Analogies with Diabetes Mellitus. Cancers (Basel) 2020;12:E3226. [PMID: 33147695 DOI: 10.3390/cancers12113226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Ruocco N, Costantini S, Costantini M. Blue-Print Autophagy: Potential for Cancer Treatment. Mar Drugs 2016;14:E138. [PMID: 27455284 DOI: 10.3390/md14070138] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
16 Albatany M, Ostapchenko VG, Meakin S, Bartha R. Brain tumor acidification using drugs simultaneously targeting multiple pH regulatory mechanisms. J Neurooncol 2019;144:453-62. [PMID: 31392597 DOI: 10.1007/s11060-019-03251-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
17 Wu D, Qiu T, Zhang Q, Kang H, Yuan S, Zhu L, Zhu R. Systematic toxicity mechanism analysis of proton pump inhibitors: an in silico study. Chem Res Toxicol 2015;28:419-30. [PMID: 25626140 DOI: 10.1021/tx5003782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
18 He J, Shi XY, Li ZM, Pan XH, Li ZL, Chen Y, Yan SJ, Xiao L. Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer. BMC Mol Cell Biol 2019;20:49. [PMID: 31718559 DOI: 10.1186/s12860-019-0227-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
19 Sun L, Liu Y, Liu X, Wang R, Gong J, Saferali A, Gao W, Ma A, Ma H, Turvey SE, Fung SY, Yang H. Nano-Enabled Reposition of Proton Pump Inhibitors for TLR Inhibition: Toward A New Targeted Nanotherapy for Acute Lung Injury. Adv Sci (Weinh) 2021;:e2104051. [PMID: 34816630 DOI: 10.1002/advs.202104051] [Reference Citation Analysis]
20 Canitano A, Iessi E, Spugnini EP, Federici C, Fais S. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Lett 2016;376:278-83. [PMID: 27084522 DOI: 10.1016/j.canlet.2016.04.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
21 Gu D, Jin H, Jin G, Wang C, Wang N, Hu F, Luo Q, Chu W, Yao M, Qin W. The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity. Cancer Lett 2016;379:107-16. [PMID: 27241665 DOI: 10.1016/j.canlet.2016.05.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
22 Santos JM, Hussain F. VD3 mitigates breast cancer aggressiveness by targeting V-H+-ATPase. The Journal of Nutritional Biochemistry 2019;70:185-93. [DOI: 10.1016/j.jnutbio.2019.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Liu J, Chen Q, Feng L, Liu Z. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement. Nano Today 2018;21:55-73. [DOI: 10.1016/j.nantod.2018.06.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 88] [Article Influence: 30.8] [Reference Citation Analysis]
24 Kumar A, Kant S, Singh SM. α-Cyano-4-hydroxycinnamate induces apoptosis in Dalton’s lymphoma cells: role of altered cell survival-regulatory mechanisms. Anti-Cancer Drugs 2013;24:158-71. [DOI: 10.1097/cad.0b013e3283586743] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
25 Lee YY, Jeon HK, Hong JE, Cho YJ, Ryu JY, Choi JJ, Lee SH, Yoon G, Kim WY, Do IG, Kim MK, Kim TJ, Choi CH, Lee JW, Bae DS, Kim BG. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget 2015;6:35040-50. [PMID: 26418900 DOI: 10.18632/oncotarget.5319] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
26 Yoneda T, Hata K, Nakanishi M, Nagae M, Nagayama T, Wakabayashi H, Nishisho T, Sakurai T, Hiraga T. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone. 2011;48:100-105. [PMID: 20637323 DOI: 10.1016/j.bone.2010.07.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
27 Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, Haier J, Hummel R. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73. [PMID: 25175076 DOI: 10.1186/s13046-014-0073-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
28 Koltai T. Cancer: fundamentals behind pH targeting and the double-edged approach. Onco Targets Ther 2016;9:6343-60. [PMID: 27799782 DOI: 10.2147/OTT.S115438] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
29 Nakanishi M, Morita Y, Hata K, Muragaki Y. Acidic microenvironments induce lymphangiogenesis and IL-8 production via TRPV1 activation in human lymphatic endothelial cells. Exp Cell Res 2016;345:180-9. [PMID: 27312995 DOI: 10.1016/j.yexcr.2016.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
30 Song Q, Meng B, Xu H, Mao Z. The emerging roles of vacuolar-type ATPase-dependent Lysosomal acidification in neurodegenerative diseases. Transl Neurodegener 2020;9:17. [PMID: 32393395 DOI: 10.1186/s40035-020-00196-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
31 Zhao Y, Lu Y, Ma J, Zhu L. Synthesis and Evaluation of Cleistanthin A Derivatives as Potent Vacuolar H + -ATPase Inhibitors. Chem Biol Drug Des 2015;86:691-6. [DOI: 10.1111/cbdd.12538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
32 Takeda A, Takano N, Kokuba H, Hino H, Moriya S, Abe A, Hiramoto M, Tsukahara K, Miyazawa K. Macrolide antibiotics enhance the antitumor effect of lansoprazole resulting in lysosomal membrane permeabilization‑associated cell death. Int J Oncol 2020;57:1280-92. [PMID: 33173988 DOI: 10.3892/ijo.2020.5138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Spugnini EP, Buglioni S, Carocci F, Francesco M, Vincenzi B, Fanciulli M, Fais S. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014;12:225. [PMID: 25143012 DOI: 10.1186/s12967-014-0225-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
34 Song T, Jeon HK, Hong JE, Choi JJ, Kim TJ, Choi CH, Bae DS, Kim BG, Lee JW. Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer. Cancer Res Treat 2017;49:595-606. [PMID: 27669706 DOI: 10.4143/crt.2016.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
35 Hussein NA, Malla S, Pasternak MA, Terrero D, Brown NG, Ashby CR Jr, Assaraf YG, Chen ZS, Tiwari AK. The role of endolysosomal trafficking in anticancer drug resistance. Drug Resist Updat 2021;57:100769. [PMID: 34217999 DOI: 10.1016/j.drup.2021.100769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Moore D, Walker SI, Levin M. Cancer as a disorder of patterning information: computational and biophysical perspectives on the cancer problem. Converg Sci Phys Oncol 2017;3:043001. [DOI: 10.1088/2057-1739/aa8548] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
37 Koltai T, Cardone RA, Reshkin SJ. Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer. Int J Mol Sci 2019;20:E5438. [PMID: 31683667 DOI: 10.3390/ijms20215438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767-777. [PMID: 21921921 DOI: 10.1038/nrd3554] [Cited by in Crossref: 1005] [Cited by in F6Publishing: 969] [Article Influence: 91.4] [Reference Citation Analysis]
39 Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, Baba Y. Acidic extracellular microenvironment and cancer. Cancer Cell Int 2013;13:89. [PMID: 24004445 DOI: 10.1186/1475-2867-13-89] [Cited by in Crossref: 684] [Cited by in F6Publishing: 639] [Article Influence: 76.0] [Reference Citation Analysis]
40 Turner CA, Watson SJ, Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 2012;76:160-74. [PMID: 23040813 DOI: 10.1016/j.neuron.2012.08.037] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 9.6] [Reference Citation Analysis]
41 Zhang JL, Liu M, Yang Q, Lin SY, Shan HB, Wang HY, Xu GL. Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. World J Gastroenterol 2017; 23(14): 2575-2584 [PMID: 28465642 DOI: 10.3748/wjg.v23.i14.2575] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
42 Zhao Y, Zhang R, Lu Y, Ma J, Zhu L. Synthesis and bioevaluation of heterocyclic derivatives of Cleistanthin-A. Bioorganic & Medicinal Chemistry 2015;23:4884-90. [DOI: 10.1016/j.bmc.2015.05.033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
43 Li JQ, Chen M, Zou XP. PPIs reverse multidrug resistance to chemotherapy in gastric cancer by inhibiting vacuolar H+-ATPase signal pathway. Shijie Huaren Xiaohua Zazhi 2011; 19(31): 3201-3206 [DOI: 10.11569/wcjd.v19.i31.3201] [Reference Citation Analysis]
44 Salerno M, Avnet S, Bonuccelli G, Hosogi S, Granchi D, Baldini N. Impairment of lysosomal activity as a therapeutic modality targeting cancer stem cells of embryonal rhabdomyosarcoma cell line RD. PLoS One 2014;9:e110340. [PMID: 25329465 DOI: 10.1371/journal.pone.0110340] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
45 Matboli M, ElGwad AA, Hasanin AH, El-Tawdi A, Habib EK, Elmansy RA, Ibrahim D, Shehata H, Tash F. Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2-acetamidofluorene. J Cell Biochem 2019;120:14946-59. [PMID: 31009125 DOI: 10.1002/jcb.28757] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Bosnjak T, Solberg R, Hemati PD, Jafari A, Kassem M, Johansen HT. Lansoprazole inhibits the cysteine protease legumain by binding to the active site. Basic Clin Pharmacol Toxicol 2019;125:89-99. [PMID: 30916878 DOI: 10.1111/bcpt.13230] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
47 Chen M, Lu J, Wei W, Lv Y, Zhang X, Yao Y, Wang L, Ling T, Zou X. Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo. Onco Targets Ther 2018;11:6705-22. [PMID: 30349304 DOI: 10.2147/OTT.S161198] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
48 Brisson L, Reshkin SJ, Goré J, Roger S. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol. 2012;91:847-860. [PMID: 22673002 DOI: 10.1016/j.ejcb.2012.04.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
49 Hazzan R, Darawsha U, Neeman Z, Aviv A. Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients. Expert Rev Hematol 2021;14:503-7. [PMID: 33899663 DOI: 10.1080/17474086.2021.1920011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Iessi E, Logozzi M, Mizzoni D, Di Raimo R, Supuran CT, Fais S. Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy. Metabolites 2017;8:E2. [PMID: 29295495 DOI: 10.3390/metabo8010002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
51 Mcintyre A, Harris AL. The Role of pH Regulation in Cancer Progression. In: Cramer T, A. Schmitt C, editors. Metabolism in Cancer. Cham: Springer International Publishing; 2016. pp. 93-134. [DOI: 10.1007/978-3-319-42118-6_5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
52 Spugnini EP, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, Garcìa AG, Harguindey S, Fais S. Proton channels and exchangers in cancer. Biochim Biophys Acta 2015;1848:2715-26. [PMID: 25449995 DOI: 10.1016/j.bbamem.2014.10.015] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 14.8] [Reference Citation Analysis]
53 Takahashi K, Ohta T. Low pH enhances 2-aminoethoxydiphenyl borate-induced cell death of PC12 cells. Toxicology Letters 2012;215:161-6. [DOI: 10.1016/j.toxlet.2012.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Kulshrestha A, Katara GK, Ginter J, Pamarthy S, Ibrahim SA, Jaiswal MK, Sandulescu C, Periakaruppan R, Dolan J, Gilman-Sachs A, Beaman KD. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells. Mol Oncol 2016;10:789-805. [PMID: 26899534 DOI: 10.1016/j.molonc.2016.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
55 Fogarty FM, O'keeffe J, Zhadanov A, Papkovsky D, Ayllon V, O'connor R. HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H+ ATPase. Oncogene 2014;33:4653-63. [DOI: 10.1038/onc.2013.403] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
56 Zhang Z, Ma J, Zhu L, Zhao Y. Synthesis and identification of cytotoxic diphyllin glycosides as vacuolar H+-ATPase inhibitors. European Journal of Medicinal Chemistry 2014;82:466-71. [DOI: 10.1016/j.ejmech.2014.06.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
57 Luong B, Schwenk R, Bräutigam J, Müller R, Menche D, Bischoff I, Fürst R. The vacuolar-type ATPase inhibitor archazolid increases tumor cell adhesion to endothelial cells by accumulating extracellular collagen. PLoS One 2018;13:e0203053. [PMID: 30204757 DOI: 10.1371/journal.pone.0203053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
58 Granja S, Tavares-Valente D, Queirós O, Baltazar F. Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Semin Cancer Biol 2017;43:17-34. [PMID: 28065864 DOI: 10.1016/j.semcancer.2016.12.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
59 Lunova M, Smolková B, Lynnyk A, Uzhytchak M, Jirsa M, Kubinová Š, Dejneka A, Lunov O. Targeting the mTOR Signaling Pathway Utilizing Nanoparticles: A Critical Overview. Cancers (Basel) 2019;11:E82. [PMID: 30642006 DOI: 10.3390/cancers11010082] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
60 Hebert KA, Jaramillo S, Yu W, Wang M, Veeramachaneni R, Sandulache VC, Sikora AG, Bonnen MD, Annapragada AV, Corry D, Kheradmand F, Pandita RK, Ludwig MS, Pandita TK, Huang S, Coarfa C, Grimm SL, Perera D, Miles G, Ghebre YT. Esomeprazole enhances the effect of ionizing radiation to improve tumor control. Oncotarget 2021;12:1339-53. [PMID: 34262645 DOI: 10.18632/oncotarget.28008] [Reference Citation Analysis]
61 Patil R, Kulshrestha A, Tikoo A, Fleetwood S, Katara G, Kolli B, Seibel W, Gilman-Sachs A, Patil SA, Beaman KD. Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H⁺)-ATPase Inhibitors. Molecules 2017;22:E1559. [PMID: 28926955 DOI: 10.3390/molecules22091559] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
62 Lugini L, Federici C, Borghi M, Azzarito T, Marino ML, Cesolini A, Spugnini EP, Fais S. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem 2016;31:538-45. [PMID: 26018420 DOI: 10.3109/14756366.2015.1046062] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
63 Zhou SJ, Wang SQ, Ma YY, Tang LY, Shi YF, Liang B, Chen Y, Yu K. Association of proton pump inhibitors with the occurrence of gut-derived bacteraemia in patients with haematological malignancy after chemotherapy. Hematology 2016;21:332-7. [PMID: 27077765 DOI: 10.1080/10245332.2016.1142711] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
64 Kallunki T, Olsen OD, Jäättelä M. Cancer-associated lysosomal changes: friends or foes? Oncogene 2013;32:1995-2004. [DOI: 10.1038/onc.2012.292] [Cited by in Crossref: 161] [Cited by in F6Publishing: 152] [Article Influence: 16.1] [Reference Citation Analysis]
65 Alfarouk KO, Shayoub ME, Muddathir AK, Elhassan GO, Bashir AH. Evolution of Tumor Metabolism might Reflect Carcinogenesis as a Reverse Evolution process (Dismantling of Multicellularity). Cancers (Basel) 2011;3:3002-17. [PMID: 24310356 DOI: 10.3390/cancers3033002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
66 Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10:134. [PMID: 22738135 DOI: 10.1186/1479-5876-10-134] [Cited by in Crossref: 211] [Cited by in F6Publishing: 208] [Article Influence: 21.1] [Reference Citation Analysis]
67 Harguindey S, Alfarouk K, Polo Orozco J, Fais S, Devesa J. Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era. Int J Mol Sci 2020;21:E7475. [PMID: 33050492 DOI: 10.3390/ijms21207475] [Reference Citation Analysis]
68 Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, Friedman GK, Hjelmeland AB. Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics 2021;11:665-83. [PMID: 33391498 DOI: 10.7150/thno.41692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
69 Spugnini EP, Baldi A, Buglioni S, Carocci F, de Bazzichini GM, Betti G, Pantaleo I, Menicagli F, Citro G, Fais S. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011;9:221. [PMID: 22204495 DOI: 10.1186/1479-5876-9-221] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
70 Meehan J, Ward C, Turnbull A, Bukowski-Wills J, Finch AJ, Jarman EJ, Xintaropoulou C, Martinez-Perez C, Gray M, Pearson M, Mullen P, Supuran CT, Carta F, Harrison DJ, Kunkler IH, Langdon SP. Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells. Oncotarget 2017;8:42857-75. [PMID: 28476026 DOI: 10.18632/oncotarget.17143] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]